← Back to Clinical Trials
Recruiting NCT06290544

NCT06290544 Cardiovascular Risk Assessment in a Cohort of Italian Patients With Type 1 Diabetes Mellitus (CARDT1)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06290544
Status Recruiting
Phase
Sponsor Centro Cardiologico Monzino
Condition Diabetes Mellitus, Type 1
Study Type INTERVENTIONAL
Enrollment 200 participants
Start Date 2021-11-29
Primary Completion 2026-07

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Standard of care plus additional examinations

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 200 participants in total. It began in 2021-11-29 with a primary completion date of 2026-07.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This is a multicenter prospective collection of data with diagnostic procedures different from standard clinical care in a specific cohort of patients, aimed to evaluate cardiovascular risk stratification with the European Society of Cardiology (ESC)/European Association for the Study of Diabetes (EASD) guidelines and "The Steno Type 1 Risk Engine" algorithm. The correlation between CVD risk, atherosclerosis, and microvascular complications of diabetes (retinopathy, nephropathy, and neuropathy) will then be evaluated, and the impact of glycemic variability and other glucose metrics on vascular damage will be characterized. The investigators plan to enroll at least 200 consecutive type 1 diabetes mellitus (T1DM) patients who meet all the inclusion criteria and none of exclusion criteria.

Eligibility Criteria

Inclusion Criteria: * Diagnosis of type 1 diabetes mellitus. * Age ≥ 18 years. * Signed Informed consent Exclusion Criteria: * Age \< 18 years. * Pregnancy in progress. * Type 2 diabetes mellitus. * Secondary diabetes

Contact & Investigator

Central Contact

Stefano Genovese, MD

✉ stefano.genovese@cardiologicomonzino.it

📞 +390258002327

Principal Investigator

Stefano Genovese, MD

PRINCIPAL INVESTIGATOR

IRCCS Centro Cardiologico Monzino

Frequently Asked Questions

Who can join the NCT06290544 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Diabetes Mellitus, Type 1. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06290544 currently recruiting?

Yes, NCT06290544 is actively recruiting participants. Contact the research team at stefano.genovese@cardiologicomonzino.it for enrollment information.

Where is the NCT06290544 trial being conducted?

This trial is being conducted at Milan, Italy, Monza, Italy.

Who is sponsoring the NCT06290544 clinical trial?

NCT06290544 is sponsored by Centro Cardiologico Monzino. The principal investigator is Stefano Genovese, MD at IRCCS Centro Cardiologico Monzino. The trial plans to enroll 200 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology